OSLO, Norway--(BUSINESS WIRE)--Therapeutic vaccine company Vaccibody today announced that it has received a Euros 2 million grant from the Norwegian Research Council’s BIA Program to develop a novel therapeutic vaccine against precancerous lesions of the cervix. The new vaccine, VB10.16, will be based on the company’s Vaccibody DNA vaccine platform, which targets antigen-presenting cells. The introduction of screening programmes has had a major impact on the incidence and mortality of invasive cervical cancer, and for example 11,000 new cases are detected in the US annually. However it is estimated that large numbers of older, disadvantaged and immigrant women remain outside such programmes.
